What should you know before buying stock in ImmunityBio Inc (IBRX)

ImmunityBio Inc (NASDAQ: IBRX) is -8.76% lower on its value in year-to-date trading and has touched a low of $1.21 and a high of $6.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IBRX stock was last observed hovering at around $43.93M in the last trading session, with the day’s loss setting it -39.62%.

Currently trading at $4.31, the stock is N/A and -30.51% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.17 and changing 4.58% at the moment leaves the stock N/A off its SMA200. IBRX registered 11.71% gain for a year compared to 6-month gain of 163.98%. The firm has a 50-day simple moving average (SMA 50) of $6.14k and a 200-day simple moving average (SMA200) of -$10.88.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 9.31% loss in the last 1 month and extending the period to 3 months gives it a 33.53%, and is 10.63% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.35% over the week and 10.11% over the month.

Profit margin for the company is -82377.52%. Distance from 52-week low is 278.51% and -33.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-152.07%).

ImmunityBio Inc quarterly earnings per share for the current quarter are estimated at -$0.18 with sales reaching $20k over the same period.The EPS is expected to grow by 10.58% this year, but quarterly earnings will post 112.50% year-over-year. Quarterly sales are estimated to shrink -72.60% in year-over-year returns.

ImmunityBio Inc (IBRX) Top Institutional Holders

202 institutions hold shares in ImmunityBio Inc (IBRX), with institutional investors hold 39.52% of the company’s shares. The shares outstanding are 421.57M, and float is at 130.69M with Short Float at 33.62%. Institutions hold 7.76% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 14.68 million shares valued at $67.21 million. The investor’s holdings represent 2.20% of the IBRX Shares outstanding. As of Sep 29, 2023, the second largest holder is Blackrock Inc. with 10.81 million shares valued at $49.51 million to account for 1.62% of the shares outstanding. The other top investors are Armistice Capital, LLC which holds 3.48 million shares representing 0.52% and valued at over $15.92 million, while Geode Capital Management, LLC holds 0.42% of the shares totaling 2.81 million with a market value of $12.85 million.

ImmunityBio Inc (IBRX) Insider Activity

A total of 6 insider transactions have happened at ImmunityBio Inc (IBRX) in the last six months, with sales accounting for 0 and purchases happening 6 times. The most recent transaction is an insider purchase by BLASZYK MICHAEL D ,the company’sDirector. SEC filings show that BLASZYK MICHAEL D bought 71,915 shares of the company’s common stock on Jun 05 at a price of $2.75 per share for a total of $0.2 million. Following the purchase, the insider now owns 71915.0 shares.

ImmunityBio Inc disclosed in a document filed with the SEC on Jun 02 that Brennan John Owen (Director) bought a total of 25,000 shares of the company’s common stock. The trade occurred on Jun 02 and was made at $2.83 per share for $70700.0. Following the transaction, the insider now directly holds 25000.0 shares of the IBRX stock.

Still, SEC filings show that on Jun 01, Clark Wesley (Director) acquired 7,000 shares at an average price of $2.91 for $20370.0. The insider now directly holds 8,000 shares of ImmunityBio Inc (IBRX).